Arcus Biosciences Inc

RCUS is in Stage 3 distribution and has triggered a support failure pattern with price closing sharply below key intra-month support on high volume, signaling committed selling. Short-term momentum is negative with price rejected at the 9/20/50 EMAs and approaching the 200-day SMA, while the long-term uptrend remains intact above the rising 200-day SMA. The medium-term bias is bearish, and negative short-term conditions favor immediate downside participation. A decisive reclaim of the broken support band and EMAs would invalidate the bearish posture.

• ↑Management forecasts $5–10B peak sales for casdatifan in RCC market
• ↑$775M cash as of Q2 2026 funds operations into H2 2028 amid R&D spending cuts
• ↓Q2 2026 net loss of $91M and full-year revenue guidance of $65–75M underscore weak profitability